To sell pharmaceutical products in the United States, you need a stack of authorizations rather than a single license: FDA registration for the facility that makes or handles the drug, DEA registration if any product is a controlled substance, a wholesale distributor or manufacturer permit from the pharmacy board in every state you ship to, and an approved New Drug Application or Abbreviated New Drug Application for each product itself. Each layer targets a different piece of drug safety and supply chain integrity, and skipping any one of them can result in seized shipments, criminal penalties, or a permanent bar from the industry.
Register Your Facility With the FDA
Every company that manufactures, repacks, relabels, or salvages drugs for commercial distribution has to register with the FDA before selling a single unit. This applies to both domestic and foreign facilities. You register each physical location and list every drug that location handles through the FDA’s Electronic Drug Registration and Listing System (eDRLS), providing the establishment’s name, address, and phone number.1eCFR. 21 CFR Part 207 – Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs
Registration itself carries no separate filing fee, but companies with approved drug applications owe an annual prescription drug program fee under the Prescription Drug User Fee Act. For fiscal year 2026, that program fee is $442,213 per qualifying establishment, owed regardless of how many products the facility makes.2Federal Register. Prescription Drug User Fee Rates for Fiscal Year 2026
Register With the DEA if You Handle Controlled Substances
Any company that manufactures or distributes controlled substances needs a separate registration from the Drug Enforcement Administration. You apply using DEA Form 225. Manufacturers pay $3,699 per year and distributors pay $1,850 per year, while research-only registrations cost $296 annually.3Federal Register. Registration and Reregistration Fees for Controlled Substance and List I Chemical Registrants
The application requires you to disclose which drug schedules (I through V) you’ll handle and to describe your facility’s security measures. The DEA cross-checks your business details against state incorporation records, so any mismatch between your application and your state filing can trigger a rejection.4Department of Justice. Registration – Diversion Control Division Registrations renew annually, and an active DEA registration is a prerequisite for handling any scheduled substance.
Get a State License in Every State Where You Ship
Federal registration alone doesn’t authorize you to operate. Nearly every state requires a separate wholesale distributor or manufacturer permit issued by its board of pharmacy. Applications typically require surety bonds in the range of $25,000 to $100,000, along with background checks and fingerprinting for the company’s designated representatives. Application fees range from a few hundred to several thousand dollars depending on jurisdiction.
Most states require you to name a designated representative who serves as the point of accountability for your facility. This person typically needs at least one year of paid experience in pharmaceutical distribution or a related field, and some states impose stricter requirements. Their personal history, including criminal background, is scrutinized as part of the licensing process. State licenses generally renew annually, and late renewals can trigger fines or a lapse in your authority to distribute.
If you operate in multiple states, you’ll need a nonresident wholesale distributor license in each state where you ship products. Some states also require out-of-state operations to employ a pharmacist licensed in that state. Failing to hold the right license in even one state can result in seized shipments at the border, so check each target state’s board of pharmacy for its specific requirements.
Get Each Product Approved: NDA or ANDA
Before any drug can be legally sold, it needs FDA approval through one of two main pathways. A New Drug Application (NDA) is the vehicle for brand-name products; it requires the full story of the drug, including clinical trial data proving safety and effectiveness, manufacturing details, and proposed labeling.5U.S. Food and Drug Administration. New Drug Application (NDA) An Abbreviated New Drug Application (ANDA) is the pathway for generic drugs, which skip the expensive clinical trials by demonstrating that the generic version is bioequivalent to the already-approved brand-name drug.6U.S. Food and Drug Administration. Abbreviated New Drug Application (ANDA)
For fiscal year 2026, an NDA requiring clinical data carries a fee of $4,682,003.7Federal Register. Prescription Drug User Fee Rates for Fiscal Year 2026 An ANDA filing costs $358,247.8Federal Register. 9U.S. Food and Drug Administration. Electronic Common Technical Document (eCTD)
Once the FDA accepts an NDA for filing, the standard review clock is 10 months. Drugs that represent a significant improvement over existing treatments may qualify for priority review, which shortens the target to 6 months.10U.S. Food and Drug Administration. Priority Review These are target dates, not guarantees.
If the FDA finds problems, it issues a Complete Response Letter (CRL) describing every deficiency it identified during review and possibly recommending fixes.11eCFR. 21 CFR 314.110 – Complete Response Letter to the Applicant You can resubmit with corrections, withdraw the application, or let it be treated as withdrawn after a year of inaction. A minor resubmission triggers a new 2-month review cycle; a major resubmission starts a new 6-month cycle. Final approval almost always requires a pre-approval inspection where investigators verify that your physical setup, equipment, and processes match what you described.
Meet Facility, Labeling, and Supply Chain Rules Before You Ship
Your physical facility must meet Current Good Manufacturing Practice (cGMP) standards before the FDA will approve any product made there. Written procedures are required for cleaning and maintaining every piece of equipment used in manufacturing, and each major piece of equipment needs a log showing the date, time, product, and lot number of every batch processed, signed and dated by the people who perform and verify the work.12eCFR. Part 211 Current Good Manufacturing Practice for Finished Pharmaceuticals Environmental controls matter especially for biologics and temperature-sensitive products, which need validated cold-chain storage, humidity monitoring, and documented procedures for handling deviations. Inspectors compare what they see on the ground with what your application describes, and discrepancies are among the most common findings that delay approvals.
Labeling rules are equally exacting. Every drug label must include directions for use written so that a layperson can use the drug safely for its intended purpose, with minimum type sizes (no smaller than 6-point for body text, headings at least 8-point or 2 points larger than surrounding text), adequate background contrast, and no designs that obscure required information.13eCFR. 21 CFR Part 201 – Labeling Every data point on the label must match the findings from your clinical and chemical reports exactly. If your trial showed a 3% incidence of a particular side effect, the label must reflect that figure. Discrepancies are one of the fastest routes to a Complete Response Letter.
Facilities that store controlled substances face additional physical security requirements. Federal regulations require effective controls against theft and diversion, including reinforced storage vaults, alarm systems, and restricted access zones, scaled to the quantity and schedule of substances you hold.14eCFR. 21 CFR 1301.71 – Security Requirements Generally Passing a DEA security inspection is a prerequisite for receiving and keeping your controlled substance registration.
The Drug Supply Chain Security Act requires every participant in the pharmaceutical supply chain to track and trace products at the package level using an interoperable electronic system, with product tracing information included in each transaction.15FDA. Drug Supply Chain Security Act (DSCSA)16U.S. Food and Drug Administration. Drug Supply Chain Security Act Product Tracing Requirements – Frequently Asked Questions The stabilization-period exemptions have already expired for manufacturers (May 2025) and wholesale distributors (August 2025). Small dispensers with 25 or fewer pharmacy staff have until November 27, 2026.17U.S. Food and Drug Administration. Waivers and Exemptions Beyond the Stabilization Period Building serialization and tracking infrastructure before launch is far cheaper than retrofitting after.
Keep Your Authorizations Active After Launch
Getting a drug approved is only the halfway point. When a serious and unexpected adverse drug experience occurs, you must file a 15-day “Alert report” with the FDA from the date you first learn about it.18eCFR. 21 CFR 314.80 – Postmarketing Reporting of Adverse Drug Experiences “Serious” includes outcomes such as death, hospitalization, persistent disability, or birth defects.
Beyond individual adverse event reports, you must file an annual report within 60 days of your drug’s approval anniversary each year. It has to cover new safety information, distribution data (including quantities shipped domestically and internationally), any labeling changes, updates on ongoing or completed studies, and an estimate of patient exposure with special reference to pediatric populations where applicable.19eCFR. 21 CFR 314.81 – Other Postmarketing Reports
Promotional material carries its own rules. Advertisements must present a fair balance between the drug’s benefits and its known risks; any claim that omits risk information or overstates effectiveness is treated as misbranding.20eCFR. 21 CFR Part 202 – Prescription Drug Advertising For most approved drugs, you submit copies of all promotional labeling and advertisements to the FDA’s Office of Prescription Drug Promotion at the time you first distribute or publish them. Drugs approved under the accelerated approval pathway are different: they must submit promotional materials at least 30 days before dissemination during an initial post-approval period.21eCFR. 21 CFR 314.550 – Promotional Materials Warning Letters demand immediate correction, and repeated violations can escalate to misbranding charges.
Penalties for Selling Without the Right Licenses
Introducing a misbranded or adulterated drug into interstate commerce is a prohibited act under federal law.22Office of the Law Revision Counsel. 21 US Code 331 – Prohibited Acts A first offense without fraud carries up to one year in prison and a $1,000 fine. A second offense, or any violation committed with intent to defraud, raises the ceiling to three years and a $10,000 fine.23Office of the Law Revision Counsel. 21 US Code 333 – Penalties
The most serious violations carry heavier penalties:
- Knowing adulteration likely to cause serious harm or death: up to 20 years in prison and a $1,000,000 fine.
- Knowingly selling or distributing drug samples, or importing drugs in violation of federal law: up to 10 years in prison and a $250,000 fine.
- Selling counterfeit drugs: up to 10 years in prison, with fines set under federal sentencing guidelines.
These criminal penalties apply on top of civil monetary penalties, which the FDA adjusts annually for inflation. The agency can also revoke your marketing authorization, seize products already in commerce, and seek court injunctions that shut down operations entirely.23Office of the Law Revision Counsel. 21 US Code 333 – Penalties